Abstract
Background: Amylin/IAPP is a 37 amino acid neuropeptide hormone. Amylin forms oligomers in diabetic conditions when loss of insulin secretion occurs. These amylin oligomers are implicated in development and poor prognosis of type 2 DM. Amylin oligomers are shown to induce diabetes-associated secondary complications. In human amylin over expressed rat, and human studies, it is shown that amylin oligomers lead to diabetes-associated cardiomyopathy, neuropathy and nephropathy. There is an immediate requirement to develop novel inhibitor for amylin oligomers towards preventing these complications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
